PD-1/PD-L1 inhibitors in monotherapy and, more recently, in combination with chemotherapy or CTLA-4 inhibitors represent possible choices for the first-line therapy of advanced NSCLC. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.